Prostaglandins are widely used in the prevention and healing of non-steroidal antiinflammatory drug (NSAID) induced gastric and duodenal ulcers, but their longterm effect on the human gastric mucosa is unknown. This study assessed the effect of coadministration of prostaglandins with NSAIDs on the histology of the gastroduodenal mucosa. Histological appearances (using the Sydney system) of gastric biopsy specimens from 180 patients receiving longterm NSAID treatment of whom 90 had been receiving misoprostol (400-800 ,ug/day) for one to two years were studied. 
longterm effect on the human gastric mucosa is unknown. This study assessed the effect of coadministration of prostaglandins with NSAIDs on the histology of the gastroduodenal mucosa. Histological appearances (using the Sydney system) of gastric biopsy specimens from 180 patients receiving longterm NSAID treatment of whom 90 had been receiving misoprostol (400-800 ,ug/day) for one to two years were studied. Both groups of patients were comparable with regard to clinical and demographic details. There was no significant difference (p>0.1) in the prevalence of chronic gastritis (total, corpus or antrum only) between patients receiving (36 of 90 (40%)) or not receiving misoprostol (35 of 90 (39%) Because of the high prevalence of gastric and duodenal ulcers in patients receiving NSAIDs and the seriousness of the possible complications, a major effort has been made to establish the efficacy of various drugs in the healing of established lesions and their possible prevention. Collectively the data to date suggest that prostaglandins, H2 receptor antagonists, and proton pump inhibitors are all of comparable efficacy in healing of NSAID associated gastric and duodenal ulcers and in preventing duodenal ulcers when given concomitantly with NSAIDs. 9 The different classes of drugs differ, however, in their efficacy to prevent the development of gastric ulcers; prostaglandins being the only agents of confirmed efficacy in double blind, placebo controlled, and comparative trials. 9 10 An increasing number of patients receiving NSAIDs are likely to be co-treated, with the prostaglandin analogue misoprostol longterm in the hope that this will reduce the frequency of NSAID associated ulcers and their serious complications (bleeding and perforation). The remaining 32 had participated in a similar study directed to investigate the site of intestinal bleeding in patients receiving NSAIDs. 14 All of these had undergone endoscopy with biopsy from standard sites (duodenum, antrum, and body) as a part of these investigation. Secondly, there was histological material from 90 patients receiving longterm NSAID treatment who had been concomitantly receiving misoprostol (400-800 ,ug/day) for one or two years. These patients had initially been recruited in a multicentre study assessing the short term (two weeks) effect of prostaglandins in the prevention and healing of NSAID induced gastroduodenal lesions. 15 The 90 patients reported on here continued taking misoprostol with their NSAID in the long term. The study at Northwick Park Hospital and the multicentre study both had common entry and exclusion criteria (Table I) .
Histological assessment All patients underwent endoscopy under sedation. Two biopsy specimens were taken from each of three sites; the duodenal bulb, the greater curve of the antrum at least 2 cm from the pylorus, and the mid greater curve of the body. In a case with ulceration close to the landmarks the samples were taken 2 cm from the crater. All samples were treated in an identical fashion, routinely formalin fixed, and paraffin processed. Sections (3 ,um) Histological assessment (Table II) The abnormal histological categories identified were chronic gastritis, reactive gastritis, and mixed patterns of the two. Thirty five patients receiving NSAIDs only had chronic gastritis compared with 36 receiving NSAIDs and misoprostol (p>0 1) (Fig 1) . Most of these were associated with the presence of H pylori (28 of 35 (73%) receiving NSAIDs alone and 31 of 36 (86%) receiving NSAIDs and misoprostol, p>0 1). There were no significant (p>0 1) differences between the two groups in the graded histological parameters (severity of inflammation, etc), as defined by the Sydney system. Seven patients receiving NSAIDs alone and four patients receiving NSAIDs and misoprostol had minimal inflammatory changes considered to be just outside the limits ofnormality.
Reactive gastritis was seen in a total of 35 patients (Fig 2) and in all cases these were When fully developed, reactive gastritis is easily identified and characterised by considerable foveolar hyperplasia associated with a comparative paucity of inflammation. In a few it may be difficult to distinguish between mild reactive changes and apparently normal mucosa.17 Reactive gastritis is not pathognomic for NSAID induced damage as it is also commonly seen in bile acid induced damage in the intact and postoperative stomach. 28 29 The mechanism of damage is uncertain. Because of the different chemical nature of NSAIDs and bile acids, reactive gastritis probably does not represent specific biochemical abnormality. Rather the histological changes may represent a tissue reaction in response to an effect on cell membranes, as both the drugs and bile have detergent properties. 30 31 Our studies show that longterm coadministration of misoprostol with NSAIDs specifically reduces the prevalence of reactive gastritis but has no effect on the H pylori associated chronic gastritis. That misoprostol either prevents the occurrence of reactive gastritis or reverses it lends further credence to the idea that such a pattern is a specific entity of which at least one of the causes is chemical induction by NSAIDs.29 That misoprostol, in diminishing the adverse mucosal effects of NSAIDs, does not influence the prevalence of H pylorn gastritis in this cohort of patients also suggests that H pylon gastritis in these patients is incidental.'9 32 Furthermore, misoprostol coadministration increases the total percentage of normal biopsy specimens at the expense of those showing reactive gastritis, the last pattern being hostile to Hpylori colonisation. It might therefore have been expected that the Helicobacter colonisation rate and concomitant chronic gastritis would have increased in the misoprostol treatment group. That this was not seen supports the broad epidemiological concept that reinfection by H pylori is a rare event in the adult population. The clinical implications of the study are more uncertain. An intriguing possibility is that the reduced prevalence of reactive gastritis in patients receiving misoprostol may somehow underlie its effect to reduce the incidence of ulcers when given concomitantly with NSAIDs.'5 33 37 This occurs despite the continuing presence of Hpylori. In this context it may be relevant that misoprostol has anti-secretory properties even at comparatively low doses.38 Collectively this could explain the findings that prostaglandins prevent NSAID associated gastric and duodenal ulcer, while H2 receptor antagonists only prevent the second,9 10 as misoprostol affects both pathogenic arms of the development of the ulcers in patients receiving NSAIDs and H2 receptor antagonists only suppress gastric acidity. This is consistent with Graham's suggestion of separate aetiologies and pathogenesis of gastroduodenal ulcers in patients receiving NSAIDs32 39 namely a direct effect of NSAIDs and an independent effect on H pylori.
In summary, we saw no worrying histopathological changes in gastric biopsy specimens of patients receiving longterm NSAIDs treatment and misoprostol. Indeed misoprostol specifically reduces the prevalence of reactive gastritis. Comparison of the findings from NSAID treated patients and those who were concomitantly taking misoprostol adds additional weight to the concept of dual gastric pathology in patients receiving NSAIDs: the reactive changes being a direct consequence of NSAIDs and largely reversible with prostaglandin treatment, and that of H pylori positive chronic gastritis, which seems to be an incidental finding in patients receiving NSAIDs and not related to NSAID treatment. 
